Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Srikanth Boddu

Vascular & Interventional Radiology Flushing, NY Medical Doctor

NPI 1225393416 CMS profile 1223899

5645 Main St, Flushing, NY 11355

Open in the dashboard

General payments

$50,954

222 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Srikanth Boddu of Flushing, NY is reported in the CMS Open Payments database as having received $50,954 across 222 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 90th percentile of Vascular & Interventional Radiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $13,333 21
2024 General $3,144 18
2023 General $12,084 38
2022 General $3,585 22
2021 General $2,645 20
2020 General $3,098 30
2019 General $13,065 73

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Srikanth Boddu
  • Vascular & Interventional Radiology median
  • Middle half of Vascular & Interventional Radiology
  • National median

In program year 2025, general payments to Srikanth Boddu were reported at $13,333. Among 3,393 Vascular & Interventional Radiology profiles paid that year, the median was $534 and the middle half received between $166 and $2,075.

Show as a table
Year Srikanth Boddu Vascular & Interventional Radiology median Middle half National median
2019 $13,065 $422 $125–$1,555 $163
2020 $3,098 $200 $68–$652 $114
2021 $2,645 $280 $99–$866 $132
2022 $3,585 $433 $137–$1,497 $149
2023 $12,084 $506 $152–$2,019 $160
2024 $3,144 $556 $175–$1,930 $164
2025 $13,333 $534 $166–$2,075 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Penumbra, Inc. $23,727 75 payments
  2. Medtronic, Inc. $12,633 35 payments
  3. Medtronic USA, Inc. $10,656 42 payments
  4. MicroVention, Inc. $1,784 14 payments
  5. Stryker Corporation $1,349 41 payments
  6. Imperative Care, INc $259 4 payments
  7. Boston Scientific Corporation $197 2 payments
  8. AbbVie, Inc. $115 1 payment
  9. Zimmer Biomet Holdings, Inc. $60 1 payment
  10. Terumo Medical Corporation $40 2 payments
  11. Other $134 5 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $36,900 17 payments
  2. Food and Beverage $9,517 190 payments
  3. Travel and Lodging $4,537 15 payments
Products named General payments · program years 2019–2025
  1. Penumbra System $9,739 18 payments
  2. KYPHON EXPRESS II KYPHOPAK TRAY $9,512 11 payments
  3. KYPHON Balloon Kyphoplasty Neuro Pain (includes Interventional) $7,417 29 payments
  4. Smart Coil $6,249 17 payments
  5. OSTEOCOOL RF ABLATION $3,239 13 payments
  6. Benchmark $2,815 8 payments
  7. Penumbra SMART Coil $2,541 4 payments
  8. KYPHON Balloon Kyphoplasty Neuro Pain (includes Interventional) $2,330 5 payments
  9. RED 72 $1,448 19 payments
  10. WEB $1,346 9 payments
  11. Other $6,915 105 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Billing to Medicare

Part B · data year 2024 · 62 billing codes

Paid by Medicare

$142,738

Of which drugs: $156

Medicare patients

394

Average age 77

Services billed

2,403

237 women, 157 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 59%
Ischemic heart disease 49%
Diabetes 48%
Atrial fibrillation 33%
Chronic kidney disease 33%
Depression 31%
Heart failure 30%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

1 product · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
UBRELVY
  • AbbVie, Inc. $115
$115 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

222 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Vascular & Interventional Radiology in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record